Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the GI tract.
• Despite common KIT/PDGFRA mutations in 85% of cases, GIST exhibits significant clinical and pathological heterogeneity.
• This heterogeneity suggests the involvement of additional regulatory factors beyond primary mutations.

Purpose of the Study:

• To explore the role of non-coding RNAs and microRNAs in GIST development and treatment.
• To investigate the potential of these molecules as biomarkers and therapeutic targets for GIST.
• To understand how genomic elements contribute to personalized GIST therapy.

Main Methods:

• Review of current literature on GIST genetics and epigenetics.
• Analysis of studies investigating long non-coding RNAs (lncRNAs) in GIST.
• Examination of research on microRNAs (miRNAs) and their role in drug resistance.

Main Results:

• lncRNAs are increasingly recognized for their functional roles in GIST, indicating potential as biomarkers and therapeutic targets.
• Certain miRNAs show promise in sensitizing GIST cells to imatinib, potentially overcoming drug resistance.
• Both coding and non-coding genomic regions are crucial for understanding GIST heterogeneity.

Conclusions:

• Aberrant expression of non-coding RNAs and miRNAs significantly contributes to GIST pathogenesis.
• Targeting lncRNAs and miRNAs could lead to improved GIST prognostication and personalized treatment strategies.
• Leveraging both coding and non-coding genomic information is key to advancing GIST therapy.